Clinical Trial Update: Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial evaluating CAR.70, engineered IL-15-transduced cord blood-derived natural killer (NK) cells, in combination with lymphodepleting che…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• B-cell Lymphoma
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Plasma Cell Leukemia
• T-cell Acute Lymphoblastic Leukemia
• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• CAR.70-engineered IL15-transduced cord blood-derived NK cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: B-Cell Lymphoma, Myelodysplastic Syndromes (MDS) | Phase 1, Phase 2 | Status: RECRUITING